Coty vs Galderma

8-K Financial Filing Analysis for Coty (2026-08-20)

On August 17, 2026, Coty Inc.'s Board of Directors approved a planned Chief Financial Officer transition. Laurent Mercier will step down as CFO effective August 31, 2026, without any disagreement with the company, and Soraya Benchikh will assume the role of CFO and principal financial officer effective September 1, 2026. Ms. Benchikh brings over twenty years of senior finance leadership, most recently serving as CFO of British American Tobacco. Her package includes an annual fixed salary of €1,165,000, target annual bonus of 150%, a €860,000 cash sign-on bonus, $2.5 million sign-on RSUs, 1.5 million stock options, and an annual $2.5 million long-term equity incentive. Additionally, the Board approved compensation increases for Executive Chairman and Interim CEO Markus Strobel—raising his base salary to $1,600,000 with a 170% target bonus and $3,000,000 annual equity grant—and a $1,275,000 retention bonus for Chief Legal Officer Kristin Blazewicz.

• Soraya Benchikh appointed as CFO effective September 1, 2026, succeeding Laurent Mercier whose departure is effective August 31, 2026.
• Benchikh receives €1.165 million base salary, 150% target bonus, €860,000 sign-on bonus, $2.5 million sign-on RSUs, 1.5 million stock options, and $2.5 million annual target LTI.
• Interim CEO Markus Strobel's base salary increased to $1.6 million (from $1.25 million) with a 170% bonus target and $3.0 million annual equity grant; CLO Kristin Blazewicz granted a $1.275 million retention bonus.

8-K Financial Filing Analysis for Coty (2026-09-11)

Coty Inc. reported formal leadership transition terms for outgoing Chief Financial Officer Laurent Mercier following the appointment of Soraya Benchikh as CFO. Mercier stepped down as CFO on September 1, 2026, transitioning to a Strategic CEO Advisor role through June 30, 2027. Under the Transition Agreement, Mercier will maintain an annual base salary of €825,000, actively assisting with handoff duties through October 2026 before being released from active responsibilities on November 1, 2026. The agreement specifies an optional early exit acceleration starting December 20, 2026, a fixed one-time bonus of €290,000 in lieu of standard FY2026/FY2027 variable compensation, continued vesting of October 2026 equity tranches, and standard post-employment non-compete terms.

• Laurent Mercier stepped down as CFO on September 1, 2026, serving as Strategic CEO Advisor through June 30, 2027, with full duties ending October 31, 2026.
• Mercier will continue to receive an annual base salary of €825,000 and a one-time fixed bonus of €290,000, while forfeiting variable bonuses for FY2026 and FY2027.
• The Transition End Date can be accelerated at Mercier's option to no earlier than December 20, 2026, with equity scheduled to vest in October 2026 remaining eligible to vest.

Coty Strengthens U.S. Consumer Beauty Leadership with Key Appointments

Coty Inc. has announced the appointment of Kara Langan as General Manager, Consumer Beauty U.S., effective October 13, 2026. Based in New York, Langan will lead the company's commercial strategy, innovation, and brand performance across the U.S. portfolio. This appointment follows the earlier hiring of Vanessa Kidd as EVP, Lifestyle Scenting Global Brands and New Product Development, reinforcing Coty's Consumer Beauty leadership.

• Kara Langan joins Coty as General Manager, Consumer Beauty U.S., effective October 13, 2026.
• Langan will report directly to Amaury De Vallois, EVP UUCAN, with a dotted line to Gordon von Bretten, President of Consumer Beauty.
• Prior to Coty, Langan served as Chief Marketing Officer of Face and Skincare at Evermark and held senior positions at Johnson & Johnson Consumer, Elizabeth Arden, and Revlon.

Fall Clinical 2026: Galderma presents new three-year Nemluvio® data showing deep and lasting skin lesion and itch responses in patients with atopic dermatitis aged 12 and older

Galderma's latest press release announces new three-year data for Nemluvio® in atopic dermatitis, presented at Fall Clinical 2026.

EADV 2026: Galderma’s new data show sustained improvements with Nemluvio® (nemolizumab) for up to three years in patients with moderate-to-severe atopic dermatitis

Galderma announced new three-year data from the ARCADIA long-term extension study showing that Nemluvio (nemolizumab) provides sustained improvements in moderate-to-severe atopic dermatitis for up to 152 weeks. At Week 152, up to 91% of patients achieved EASI-75, up to 67% achieved near-complete skin clearance, and approximately 90% reported clinically meaningful improvements in itch and quality of life. The findings were presented at the EADV 2026 Congress in Vienna, Austria, which runs September 30 to October 3, 2026. Nemluvio is approved for both moderate-to-severe atopic dermatitis and prurigo nodularis in more than 40 countries.

• Galderma published the press release on September 30, 2026, announcing new three-year ARCADIA long-term extension data for Nemluvio (nemolizumab) in moderate-to-severe atopic dermatitis.
• At Week 152, up to 91% of patients achieved EASI-75, up to 75% achieved EASI-90, up to 67% achieved IGA 0/1, up to 88% achieved clinically meaningful itch relief, and up to 92% achieved clinically meaningful quality-of-life improvement.
• The findings were presented at the EADV 2026 Congress in Vienna, Austria, with the oral presentation scheduled for Thursday, October 1, 2026.

Galderma begins trading in the Swiss Market Index, joining Switzerland's leading blue chip companies

Galderma has been added to the Swiss Market Index (SMI), marking its inclusion among Switzerland's leading blue-chip companies. This is a major corporate milestone for the company.